L. A. Hammond

1.2k total citations
29 papers, 981 citations indexed

About

L. A. Hammond is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. A. Hammond has authored 29 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. A. Hammond's work include Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (7 papers) and Neutropenia and Cancer Infections (4 papers). L. A. Hammond is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (7 papers) and Neutropenia and Cancer Infections (4 papers). L. A. Hammond collaborates with scholars based in United States, Ireland and Australia. L. A. Hammond's co-authors include Eric K. Rowinsky, Garry Schwartz, Amita Patnaik, Anthony W. Tolcher, Daniel D. Von Hoff, Paul Statkevich, Tammy L. Edwards, Christiane Geyer, Andrew Goetz and David L. Cutler and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

L. A. Hammond

29 papers receiving 955 citations

Peers

L. A. Hammond

ONCOL

PRM

GENET

Cédric Mercier France

Miyuki Akutsu Japan

Hoo G. Chun United States

P. J. Burke United States

D. J. Th. Wagener Netherlands

Gordon Moody United States

Barbara De Moerloose Belgium

Pooja Advani United States

Suraj G. Bhansali United States

Cédric Mercier France

L. A. Hammond

569 ×1.2

ONCOL

391 ×0.9

196 ×0.6

PRM

181 ×0.6

GENET

119 ×1.1

Citations per year, relative to L. A. Hammond L. A. Hammond (= 1×) peers Cédric Mercier

Countries citing papers authored by L. A. Hammond

Since Specialization

Citations

This map shows the geographic impact of L. A. Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. A. Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. A. Hammond more than expected).

Fields of papers citing papers by L. A. Hammond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. A. Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. A. Hammond. The network helps show where L. A. Hammond may publish in the future.

Co-authorship network of co-authors of L. A. Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of L. A. Hammond. A scholar is included among the top collaborators of L. A. Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. A. Hammond. L. A. Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malone, Eoghan Ruadh, et al.. (2016). Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma. Annals of Oncology. 27. vi396–vi396. 1 indexed citations

Cunningham, Robert, et al.. (2014). Venous thromboembolism prophylaxis guideline compliance: a pilot study of augmented medication charts. Irish Journal of Medical Science (1971 -). 184(2). 469–474. 5 indexed citations

Mita, Monica, Eric K. Rowinsky, John G. Kuhn, et al.. (2005). A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer. Annals of Oncology. 17(2). 313–321. 36 indexed citations

Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 20 indexed citations

Bono, Johann S. de, Sun Young Rha, Joseph Stephenson, et al.. (2004). Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Annals of Oncology. 15(12). 1825–1833. 58 indexed citations

Mita, Alain C., A. Craig Lockhart, William Cooper, et al.. (2004). A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. Journal of Clinical Oncology. 22(14_suppl). 2025–2025. 40 indexed citations

Weiss, Geoffrey R., Alain C. Mita, Mitchell Garrison, et al.. (2004). Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w). Journal of Clinical Oncology. 22(14_suppl). 3073–3073. 1 indexed citations

Hammond, L. A., Casey Cunningham, Scot Ebbinghaus, et al.. (2004). Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3068–3068. 8 indexed citations

Tolcher, Anthony W., Stanton L. Gerson, Denis Lairon, et al.. (2003). Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer. 88(7). 1004–1011. 285 indexed citations

10.

Schwartz, Garry, Amita Patnaik, L. A. Hammond, et al.. (2003). A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Annals of Oncology. 14(5). 775–782. 36 indexed citations

11.

Rothenberg, Mace L., John G. Kuhn, Larry J. Schaaf, et al.. (2001). Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Annals of Oncology. 12(11). 1631–1641. 32 indexed citations

12.

Hammond, L. A., Susan G. Hilsenbeck, Sabine Eckhardt, et al.. (2000). Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. European Journal of Cancer. 36(18). 2430–2436. 25 indexed citations

13.

Kris, Mark G., Roy S. Herbst, Danny Rischin, et al.. (2000). Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29(1). 72–72. 55 indexed citations

14.

Britten, Carolyn D., Eric K. Rowinsky, Sharyn D. Baker, et al.. (1999). A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.. PubMed. 5(7). 1629–37. 64 indexed citations

15.

Villalona‐Calero, Miguel A., Sharyn D. Baker, L. A. Hammond, et al.. (1998). Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.. Journal of Clinical Oncology. 16(8). 2770–2779. 24 indexed citations

16.

Villalona‐Calero, Miguel A., John R. Eckardt, Howard A. Burris, et al.. (1998). A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Annals of Oncology. 9(1). 71–77. 30 indexed citations

17.

Rowinsky, Eric K., Lee Smith, Pravin Chaturvedi, et al.. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.. Journal of Clinical Oncology. 16(9). 2964–2976. 114 indexed citations

18.

Hammond, L. A., John R. Eckardt, Ram Ganapathi, et al.. (1998). A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.. PubMed. 4(6). 1459–67. 39 indexed citations

19.

Hammond, L. A., et al.. (1997). Cokeromyces recurvatus infection in a bone marrow transplant recipient. Bone Marrow Transplantation. 19(3). 301–302. 18 indexed citations

20.

Hammond, L. A., et al.. (1978). Drug supply requirements for patients discharged from hospital.. BMJ. 1(6112). 555.1–555. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact